- Home
- IEAG vs EDIT Comparison
IEAG vs EDIT Comparison
Compare IEAG & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IEAG | EDIT |
|---|---|---|
| Founded | 2025 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 436.9M | 432.8M |
| IPO Year | 2025 | 2016 |
Fundamental Metrics
Financial Performance| Metric | IEAG | EDIT |
|---|---|---|
| Price | $10.24 | $2.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $5.30 |
| AVG Volume (30 Days) | 197.6K | ★ 1.4M |
| Earning Date | N/A | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 37.50 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $31,937,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 132.64 |
| 52 Week Low | $9.97 | $1.66 |
| 52 Week High | $10.27 | $4.54 |
Technical Indicators
Market Signals| Indicator | IEAG | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 65.00 | 49.98 |
| Support Level | $10.01 | $2.77 |
| Resistance Level | $10.27 | $3.21 |
| Average True Range (ATR) | 0.02 | 0.15 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 61.11 | 52.46 |
Price Performance
Historical ComparisonAbout IEAG Infinite Eagle Acquisition Corp. Class A Ordinary Shares
Infinite Eagle Acquisition Corp is a blank check company.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.